News Search Results
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol
More news about: Innocan Pharma Corporation
Feb 09, 2026, 09:00 ET Architecting the Intelligent Lab of the Future: Abio Technologies Launches Abio Spark and Blaze at SLAS2026
scientists innovate. We design AI-first, automation-native solutions that serve as the backbone for global challenges in health, sustainability, and biotechnology.Media Contact: Prem Mohanty ([email protected]).
More news about: Abio Technologies Inc.
Feb 09, 2026, 09:00 ET Human Longevity, Inc. Welcomes Nobel Laureate Michael Levitt to Scientific Advisory Board
major diseases that impact longevity and healthspan."About Human Longevity, Inc.Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan. Through its flagship
More news about: Human Longevity, Inc.
Feb 09, 2026, 09:00 ET Architecting the Intelligent Lab of the Future: Abio Technologies Launches Abio Spark and Blaze at SLAS2026
scientists innovate. We design AI-first, automation-native solutions that serve as the backbone for global challenges in health, sustainability, and biotechnology.Media Contact Prem Mohanty [email protected]
More news about: Abio Technologies Inc.
Feb 09, 2026, 08:18 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA medicines for neurological diseases. This brings Aerska's total funds raised to-date
More news about: EQT
Feb 09, 2026, 08:16 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA medicines for neurological diseases. This brings Aerska's total funds raised to-date
More news about: EQT
Feb 09, 2026, 08:00 ET Activation Capital Expands Frontier BioHealth and Strengthens Its Continuum of Support for Life Sciences Founders
activation.capital/programs/frontierbiohealth.About Virginia Biotechnology Research Partnership AuthorityThe Virginia Biotechnology Research Partnership Authority ("Authority") is a political subdivision of the Commonwealth of Virginia created
More news about: Activation Capital
Feb 09, 2026, 08:00 ET Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided an update on patient outcomes observed in its ongoing Phase 1 ovarian
More news about: Anixa Biosciences, Inc.
Feb 09, 2026, 08:00 ET DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway
community-level immunity.About DIFF BiotechZhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end
More news about: DIFF Biotech
Feb 09, 2026, 08:00 ET 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 09, 2026, 08:00 ET Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
Bar-Ilan University and a leading expert in multiscale molecular modeling. His research integrates quantum mechanics, artificial intelligence, and biotechnology to accelerate drug discovery, ag-chemical development, and materials design. Prof. Major is a pioneer in hybrid QM/MM simulations and the developer
More news about: Evogene
Feb 09, 2026, 07:00 ET Lilly to acquire Orna Therapeutics to advance cell therapies
Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.Orna
More news about: Eli Lilly and Company
Feb 09, 2026, 06:55 ET Global Personal Care Ingredients Market Expands from US$22.5 billion in 2026 to US$32.3 Billion by 2033, Says Persistence Market Research
antimicrobial, and sensory-enhancing properties are gaining preference among manufacturers seeking cost efficiency and simplified formulations. Advances in biotechnology, green chemistry, and enzyme-based processing are enabling the development of next-generation ingredients that deliver superior performance while
More news about: Persistence Market Research Pvt. Ltd.
Feb 09, 2026, 05:37 ET 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Feb 06, 2026, 12:51 ET Tampa General's Innovation Week Returns with New Programming to Showcase Breakthroughs in Patient Care and Technology
care—where innovation converges with world‑class clinical care, exceptional academics, cutting‑edge medical research, and leading life sciences and biotechnology companies," said John Couris, president and CEO of Florida Health Sciences Center | Tampa General Hospital. "Tampa General is proud to host TGH
More news about: Tampa General Hospital
Feb 06, 2026, 08:57 ET CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy
http://www.casebioscience.com, United StatesAbout CaseBioscienceCaseBioscience is a research-driven biotechnology company developing high-quality biopreservation and culture solutions that advance cell therapy and reproductive medicine. The company's science
More news about: CaseBioscience Inc.
Feb 06, 2026, 08:00 ET Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical
More news about: Insilico Medicine
Feb 06, 2026, 07:00 ET Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB)
More news about: Delonix Bioworks
Feb 05, 2026, 12:35 ET Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
Mass., Feb. 5, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a privately held, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zenocutuzumab‑zbco for the
More news about: Partner Therapeutics, Inc.
Feb 05, 2026, 11:05 ET Active Implantable Medical Devices Market Poised for Strong Growth as Technological Innovation and Chronic Disease Burden Accelerate Adoption: Verified Market Research®
Sirona, Allergan Inc., Boston Scientific Corporation, BIOTRONIK SE & Co. KG, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co., Ltd.Market SegmentationThe Active Implantable Medical Devices Market is segmented based on:By
More news about: Verified Market Research
Feb 05, 2026, 10:59 ET K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced completion of dosing in the first patient
More news about: K36 Therapeutics
Feb 05, 2026, 10:01 ET Nanorobotics Market worth $4.52 billion by 2032 - Exclusive Report by MarketsandMarkets™
are accelerating interest in nano-enabled surgical solutions. In addition, expanding clinical research and strong investment from healthcare and biotechnology companies are supporting the rapid development of nanorobotics for nano surgery and tissue repair, positioning this application segment as the fastest-growing
More news about: MarketsandMarkets
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ: ONCY), Relay Therapeutics (NASDAQ: RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ: ZLAB), and Arrivent BioPharma (NASDAQ: AVBP) directly at the convergence of urgent unmet medical
More news about: USA News Group
Feb 05, 2026, 09:15 ET Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
www.webull.com.About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 05, 2026, 08:37 ET Global Soluble Corn Fiber Market Set to Eclipse USD 78.6 Billion by 2036 as Functional Food Reformulation Hits Critical Mass | Future Market Insights'
and lower the environmental footprint of production.At the same time, regional players such as Baolingbao Biology and Jianlong Biotechnology are expanding the market's reach in East Asia, offering localized solutions that cater to specific regional palates and regulatory standards.The
More news about: Future Market Insights